Akorn CEO says 2012 results 'fantastic' due to great execution Raj Rai, CEO, commented, "We had a fantastic 2012 as a result of great execution on many fronts by the entire organization and are reaffirming our earlier issued guidance. We are excited about the long term growth prospects of our company given the growing product pipeline and the incremental manufacturing capacities achieved through our investments in our plants in the US as well the acquisition of the manufacturing assets in India. Our focus in 2013 is on accelerating our pipeline development through further investments in R&D and on preparing our Indian location for US FDA approval."
Akorn initiated with Outperform, $50 target at William Blair William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.